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OBJECTIVES In the present prospective controlled study, we measured blood levels of cardiac troponin I
(cTnI) in patients undergoing radiofrequency (RF) catheter ablation (RFA), and we sought
to investigate the degree of myocardial injury incurred by the application of RF energy and
determine its procedural correlates.
BACKGROUND Measurement of serum creatine kinase (CK) levels after RFA may underestimate the degree
of myocardial injury due to its thermal inactivation by RFA. Cardiac troponin I is a newer,
more specific marker of myocardial injury, which may circumvent this limitation; its use in
this setting has rarely been studied.
METHODS In 118 consecutive patients, 67 men and 51 women aged 38 6 19 years undergoing RFA for
a variety of arrhythmias, cTnI and creatine kinase isoenzyme (CK-MB) levels were measured
before, immediately after and 4 to 24 h after RFA. Cardiac troponin I was also measured in
39 patients (control group) having only electrophysiologic studies (EPS) without RFA.
RESULTS All RFA procedures were uncomplicated, lasted 3.2 6 2.0 h and included delivery of 16 6
22 (median: 9) RF current applications. Baseline cTnI levels averaged 0.17 6 0.18 ng/ml, rose
to 0.88 6 1.12 at the end of RFA and to 2.19 6 2.46 at 4–24 h later. Creatine kinase
isoenzyme was found to be elevated (.6 mg/l) in 32 patients (27%), while cTnI levels were
increased ($1 ng/ml) in 80 patients (68%) (p 5 0.0001). Cardiac troponin I levels correlated
with the number of RF lesions applied (r 5 0.53, p , 0.0001), the site of RFA, being higher
with ventricular . atrial . annular lesions (p 5 0.012) and the approach to the mitral annulus
(transaortic . transseptal, p 5 0.004). In a control group of 39 patients undergoing EPS, all
but one patient had normal cTnI or CK-MB.
CONCLUSIONS The degree of myocardial injury incurred by RFA is far more accurately assessed by cTnI
levels rather than by CK-MB measurements. Cardiac troponin I levels correlate with the
number of RF lesions applied, the site of RFA and the approach to the mitral annulus. (J Am
Coll Cardiol 1999;34:1099–105) © 1999 by the American College of Cardiology
The use of radiofrequency (RF) catheter ablation has
become standard therapy for a variety of cardiac arrhythmias
(1–9). The myocardial damage incurred by the thermal
injury induced by RF current application has been consid-
ered small, due to the small size of the lesions that are
produced and, in part, due to the low levels of serum
creatine kinase (CK) measured in the postprocedural period.
However, there are two caveats that are involved in this
assumption. First, not uncommonly, an increased number of
RF lesions may be produced, especially in difficult or
demanding cases or when multiple arrhythmia foci are
targeted, leading to a large cumulative volume of myocardial
injury. Second, thermal inactivation by RF ablation of CK
could lead to underestimation of the actual degree of
myocardial injury (10).
For a long time, CK isoenzyme (CK-MB) analysis had
been the gold standard for diagnosis of myocardial injury.
Recently, cardiac troponins (I or T) have been introduced
(11–15). Troponin is the contractile regulatory protein
complex of striated muscle. It consists of three components:
troponin C (the calcium binding element), troponin I (the
tropomyosin ATPase inhibitory element) and troponin T
(the tropomyosin binding element). This complex serves to
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regulate the calcium-dependent interaction of myosin and
actin, and it plays an integral role in muscle contraction.
Troponin I exists in three distinct molecular forms found in
fast-twitch skeletal muscle, slow-twitch skeletal muscle and
heart, respectively. The cardiac isotype is specific for heart
muscle injury detection. Recent clinical studies suggest an
improved cardiac specificity for troponin I compared with
CK-MB for detection of myocardial injury in the presence
of skeletal muscle injury.
Cardiac troponin I (cTnI) has been shown to be more
sensitive and specific than CK-MB and more specific than
cardiac troponin T for the detection of minor myocardial
injury (12–14). However, cardiac troponins have rarely been
used to monitor myocardial injury after RF catheter ablation
procedures and only in a small number of patients (16,17).
The present prospective controlled study investigates in a
large cohort of 118 consecutive patients whether measure-
ment of serum levels of cTnI can detect myocardial injury
incurred during RF ablation better than CK-MB and
whether there are any procedural correlates with peak blood
levels of cTnI.
METHODS
Patients. One hundred-eighteen consecutive patients un-
dergoing RF ablation were included in the study over a span
of 24 months. These were 67 men and 51 women, aged
38 6 19 years (range 8–82) who underwent RF ablation of
accessory (n 5 48) or slow atrioventricular (AV) nodal (n 5
34) pathways, atrial foci (n 5 14), both slow pathway and
atrial foci (n 5 3), ventricular foci (n 5 15) or the AV node
(n 5 4). All patients had symptomatic tachyarrhythmias
and were diagnosed as having Wolff-Parkinson-White syn-
drome (n 5 29) or preexcitation variant (n 5 2), arrhyth-
mias related to a concealed accessory pathway (n 5 17), AV
nodal reentrant tachycardia (n 5 37), atrial tachycardia (n 5
10) or flutter (n 5 4), atrial fibrillation (n 5 4), idiopathic
ventricular tachycardia (n 5 13) (right-sided in seven and
left-sided in six) or ventricular tachycardia with underlying
tetralogy of Fallot (n 5 1) or right ventricular dysplasia (n 5
1). Electrophysiologic testing and mapping were part of the
ablation procedure and routinely preceded delivery of RF
lesions.
In the study there were also 39 patients (control group)
undergoing electrophysiologic studies (EPS) without RF
ablation consisting of 27 men and 12 women with a mean
age of 47 6 19 years. They underwent EPS for complaints
of palpitations (n 5 4), presyncope (n 5 1) or syncope (n 5
9) and for documented supraventricular (n 5 7) or ventric-
ular tachyarrhythmias (n 5 17) or persistent sinus brady-
cardia (n 5 1). All patients gave informed written consent
for the procedures.
Electrophysiologic study. The diagnostic EPS was per-
formed in the fasting state after all antiarrhythmic agents
had been discontinued for a period of at least five drug
elimination half-lives. For some patients in the control
group, EPS was performed while the patients were receiving
an antiarrhythmic drug (electropharmacologic testing).
Routinely, three 6F quadripolar electrode catheters were
introduced from the femoral vein(s) and positioned under
fluoroscopy at the high right atrium, across the tricuspid
valve for His bundle recording and at the right ventricular
apex. In patients with known preexcitation or undiagnosed
supraventricular tachycardia, a 6F steerable quadripolar
catheter was placed in the coronary sinus from the right
femoral vein. For patients undergoing electropharmacologic
testing for ventricular tachycardia, one or two electrode
catheters were inserted. Previously described standard re-
cording methods, programmed stimulation techniques, pro-
tocols and definitions were used (1–3,6–9).
Ablation procedure. After the initial location of the ar-
rhythmia focus had been determined during the EPS, a 7F
steerable quadripolar deflectable-tip catheter with a 4-mm
distal electrode and 2-5-2-mm interelectrode spacing (Cor-
dis Webster, Baldwin Park, California) was used for precise
mapping and subsequent ablation with delivery of RF
current. Access to the left heart was obtained using the
transseptal approach for ablation of left atrial foci, the
transseptal or transaortic approach for ablation of left-sided
accessory pathways (8,9) and the transaortic technique for
ablation of left-sided ventricular tachycardia foci. Patients
undergoing ablation of a left-sided arrhythmia focus re-
ceived anticoagulation with heparin.
The RF current was generated at a frequency of 500 kHz
by a conventional temperature-controlled electrosurgical
unit (Osypka 300, Grenzach-Wyhlen, Germany) and was
delivered between the distal electrode and a cutaneous
indifferent dispersive pad positioned on the posterior thorax
or left thigh. A preset target temperature of 70°C and a
maximum power of 50 W was programmed. Once the
target site was identified, 20 to 50 W of RF energy was
delivered via the ablation catheter. If a temperature level of
at least 48°C to 50°C was achieved and loss of preexcitation
(in case of manifest accessory pathways) or termination of
the tachycardia (in the case of concealed accessory pathways,
atrial or ventricular tachycardias) or accelerated junctional
rhythm (in the case of slow AV nodal pathway ablation) or
complete heart block (in the case of AV node/His bundle
ablation) occurred within 5 to 15 s, the RF application was
continued for 30 s, otherwise it was stopped and attempts at
Abbreviations and Acronyms
AV 5 atrioventricular
CK 5 creatine kinase
CK-MB 5 creatine kinase MB isoenzyme
cTnI 5 cardiac troponin I
ECG 5 electrocardiogram
EPS 5 electrophysiology study or electrophysiologic
studies
RF 5 radiofrequency
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mapping and ablation continued. If impedance rose during
ablation, RF application was interrupted, the catheter was
removed and cleaned before reinsertion. One half hour to
1 h after ablation, programmed stimulation was performed
to confirm the efficacy of ablation. After the procedure all
patients were monitored for 24 to 48 h before discharge.
During this period serial electrocardiograms (ECGs) were
obtained to evaluate for recurring arrhythmia, and an
echocardiogram was performed to evaluate for cardiac com-
plications.
Blood sample collection and cTnI, CK and CK-MB
assay. Blood samples were obtained from venous sheaths
and introduced into tube collectors containing no preserva-
tives. Within 1 h they were centrifuged for 15 min at
3,000 rpm and the supernatant serum was removed and kept
at 220°C until the assay was performed.
Serum or plasma cTnI levels were determined by the
Stratus Cardiac Troponin I assay (Dade International Inc.,
Miami, Florida), an automated, two-site immunoassay that
uses two monoclonal antibodies that are specific for the
cardiac isotype of troponin I. The lower detection limit of
the assay is 0.1 ng/ml. In our laboratory, normal values for
cTnI are ,1.0 ng/ml for healthy subjects. Serum CK and
CK-MB activity levels were measured by routine laboratory
assays, which have an upper reference limit of 230 mU/ml
for CK activity and 6 mg/l for CK-MB activity.
From each patient undergoing RF ablation, four blood
samples were taken for cTnI, CK and CK-MB measure-
ments. Initially, blood samples were obtained immediately
after insertion of the venous sheaths and before introduction
of the electrode catheters (baseline measurements). Subse-
quently, blood samples were taken upon completion of the
RF ablation procedure (post-procedural measurements). A
third sample was obtained 4 h after the end of the
procedure. A fourth sample was taken 12 h later and, only
if these measurements were higher compared with the third
sample; an extra sample was obtained at 24 h. Blood
sampling was based on previously reported patterns of
troponin kinetics (15). Due to a delay in the release of cTnI
from injured myocardial cells, most values are not usually
much elevated in samples obtained immediately after the
procedures, but abnormal values are detected at 4 h after the
procedure, while 97% of them can be detected by 12 h (15).
Serum cTnI, CK and CK-MB levels were also deter-
mined in 39 patients (control group) undergoing EPS
without RF ablation. In this group of patients, blood
samples were similarly obtained at baseline and upon
completion of the EPS, and at 4 h and 12 h later.
Patient follow-up and statistics. Periprocedurally, pa-
tients received antithrombotic therapy with aspirin and/or
ticlopidine (18). After discharge from the hospital, patients
were followed up at our arrhythmia clinic or by their
referring cardiologists every three to six months for the first
year and annually thereafter.
All values are expressed as mean 6SD; the median and
range of values are also provided for data with nonnormal
distribution. For quantitative data, statistical comparisons
were performed using analysis of variance with Fisher’s
PLSD post-hoc correction and paired or unpaired t tests as
appropriate for normal distributions, and the Mann-
Whitney, Wilcoxon signed rank, Friedman or Kruskal-
Wallis tests for nonnormal distributions. For qualitative
data, the chi-square test or the z-statistic were used.
Correlations between procedural variables and serum cTnI
levels were performed using linear and multiple regression
analysis and Spearman’s rank correlation (Statview 4.01
program, SAS Institute Inc., Cary, North Carolina). A p
value of ,0.05 was considered significant.
RESULTS
Procedural data. One hundred eighteen patients undergo-
ing RF ablation and 39 control patients having EPS alone
were included in the study. All procedures were successfully
completed without any complications. The total duration of
the procedure of RF ablation in the 118 patients averaged
3.2 6 2.0 h (Table 1), while the mean duration of the EPS
in the 39 control patients was 2.3 6 0.4 h (p 5 0.006).
Three to four catheters were used in the control group
(except in 10 patients having repeat EPS where one or two
catheters were often used) and four to five catheters were
used in the ablation group. In the ablation group, the mean
number of RF lesions was 16 6 22 (median: 9); 60 patients
had ,10 lesions, whereas 58 patients had $10 lesions. A
relatively high number of RF applications was required in
1/4 of patients in this series. These were patients with
multiple (n 5 7), uncommon (n 5 2) or right free wall (n 5
7) accessory pathways; multiple tachycardias (n 5 5); atrial
flutter (n 5 7) or macroreentry ventricular tachycardia (n 5
3).
Radiofrequency lesions were produced in the atrial myo-
cardium or atrial aspect of the annuli in 90 patients and in
the ventricular myocardium or ventricular aspect of the
annuli in 28 patients. More specifically, atrial wall lesions
were created in 17 patients, AV (annular) lesions in 86
patients and ventricular wall lesions in 15 patients. Left-
Table 1. Clinical and Procedural Characteristics of 118 Patients
Undergoing Radiofrequency Catheter Ablation






Slow pathway 1 atrial focus 3
Ventricular focus 15
AV node/His bundle 4
Number of RF lesions 16 6 22 (median: 9)
Procedure duration (h) 3.2 6 2.0
AV 5 atrioventricular; RF 5 radiofrequency.
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sided accessory pathways (n 5 27) and one slow pathway
were ablated, either on the atrial aspect of the mitral annulus
accessed via transseptal catheterization in 15 patients or on
the ventricular aspect of the annulus via a transaortic
approach in 13 patients. All right-sided accessory pathways
in 21 patients were ablated on the atrial aspect of the
tricuspid annulus.
Cardiac troponin I, CK and CK-MB levels in the
ablation group. In the ablation group of the 118 patients
during baseline measurements, the mean cTnI levels were
0.17 6 0.18 ng/ml, CK levels were 83 6 69 mU/ml and
CK-MB levels were 0.6 6 1.0 mg/l (Table 2, Fig. 1). At the
end of the RF ablation procedure, cTnI levels rose to 0.88 6
1.12 ng/ml, representing a significant increase when com-
pared with baseline (p , 0.0001), CK levels rose to 123 6
130 mU/ml (p 5 NS) and CK-MB levels rose to 2.6 6 3.4
mg/l (p , 0.001). At 4 to 24 h after the end of the ablation
procedure, cTnI levels rose to 2.19 6 2.46 ng/ml (p ,
0.0001), CK activity rose to 267 6 678 mU/ml (p 5 0.001)
and CK-MB rose to 4.9 6 5.8 mg/l (p , 0.001). Peak cTnI
levels were 2.25 6 2.47 ng/ml and most were measured at
the 4-h sampling.
Creatine kinase MB isoenzyme was found elevated
(.6 mg/l) only in 32 patients (27%), whereas cTnI levels
were increased ($1.0 ng/ml) in 80 patients (68%) (p 5
0.0001) (Table 2). Patients with normal cTnI had fewer RF
lesions, fewer ventricular lesions and shorter procedures.
Cardiac troponin I, CK and CK-MB levels in the control
group. In the control group of 39 patients undergoing EPS
without RF ablation, the baseline cTnI levels averaged
0.16 6 0.12 ng/ml, CK averaged 84 6 78 mU/ml and
CK-MB averaged 0.24 6 0.41 mg/l. At the end of EPS,
cTnI was 0.24 6 0.24 ng/ml (p 5 NS), CK was 86 6 77
mU/ml (p 5 NS) and CK-MB was 0.36 6 0.57 mg/l (p 5
NS). Within 4 to 24 h after the EPS, peak cTnI levels were
0.43 6 0.31 ng/ml (p 5 0.001), peak CK levels were 104 6
85 mU/ml (p 5 NS) and peak CK-MB levels were 0.71 6
1.16 mg/l (p 5 0.028). In the control group at all stages
before or after the EPS, all but one patient had normal
serum levels of either cTnI, CK or CK-MB; in one patient
a borderline cTnI level of 1 ng/ml was measured after the
procedure.
Procedural correlates, postprocedural data and patient
follow-up. There was a correlation of maximal (peak)
cTnI levels with the number of RF lesions applied (r 5
Table 2. Cardiac Troponin I, CK and CK-MB levels in 118 Patients Undergoing RF Ablation







Baseline cTnI 0.17 6 0.18 ng/ml
(median: 0.1; range: 0.1–0.9)
0.16 6 0.12 ng/ml
(median: 0.1; range: 0.1–0.6)
NS
Postprocedural cTnI 0.88 6 1.12 ng/ml
(median: 0.4; range: 0.1–5.3)
0.24 6 0.24 ng/ml
(median: 0.1; range: 0.1–0.9)
0.001
cTnI at 4–24 h 2.19 6 2.46 ng/ml
(median: 1.5; range: 0.1–15)
0.43 6 0.31 ng/ml
(median: 0.4; range: 0.1–1.0)
0.001
Peak cTnI 2.25 6 2.47 ng/ml
(median: 1.5; range: 0.1–15)
0.43 6 0.31 ng/ml
(median: 0.4; range: 0.1–1.0)
0.001
cTnI $ 1 ng/ml 68%* 2.6% 0.0001
Peak CK 267 6 678 mU/ml**
(median: 130; range: 36–6,509)
104 6 85 mU/ml
(median: 72; range: 29–405)
NS
Peak CK-MB 4.9 6 5.8 mg/l
(median: 3.1; range: 0.1–39.8)
0.7 6 1.2 mg/l
(median: 0.1; range: 0.1–5.2)
0.001
CK-MB . 6 mg/l 27%* 0% 0.001
*p , 0.0001; **includes a peak CK level of 6,509 mU/ml in one patient who received 7 DC cardioversions during the ablation
procedure for recurring atrial fibrillation.
CK 5 creatine kinase; CK-MB 5 creatine kinase isoenzyme; cTnI 5 cardiac troponin I; RF 5 radiofrequency.
Figure 1. Baseline, post-procedural and late (4–24 h) serum cTnI
levels in 118 patients undergoing RFA and in 39 control patients
having EPS alone. cTnI 5 cardiac troponin I; EPS 5 electro-
physiologic studies; RFA 5 radiofrequency ablation. *p 5 NS;
**p 5 0.001; *** p , 0.001.
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0.53, p , 0.0001) and a longer RFA procedure correlated
with higher cTnI levels (r 5 0.50, p , 0.0001). Patients
having $10 radiofrequency lesions (n 5 58) had higher
cTnI levels (3.26 6 2.88 ng/ml) compared with those (n 5
60) having fewer lesions (1.27 6 1.43 ng/ml) (p 5 0.0001)
(Table 3, Fig. 2). Patients (n 5 32) having only one to three
RF lesions had relatively low peak cTnI levels (1.08 6
1.13 ng/ml) but 50% of them had abnormal cTnI values,
whereas only one of these patients (3.1%) had an abnormal
CK-MB level (p , 0.001). Maximal cTnI levels also
correlated with the site of RF ablation, being higher for
ventricular versus atrial versus annular sites of RF lesions
(p 5 0.012). Also, cTnI levels were dependent on the type
of approach to the mitral annulus, being higher for the
transaortic approach versus the transseptal approach (p 5
0.004), and this result was not due to any significant
difference in the number of RF lesions applied with each
approach (20 6 22 vs. 13 6 11, p 5 NS).
Echocardiograms obtained after the procedure failed to
detect any intracardiac thrombi, wall motion abnormalities
or valvular problems. Apart from repolarization abnormal-
ities consistent with the cardiac memory phenomenon in
patients with manifest preexcitation, there were no ECG
abnormalities suggestive of ischemia after the procedures.
No patient in the RF ablation group or in the control group
suffered any coronary ischemic events during hospitalization
or during follow-up after discharge.
DISCUSSION
Cardiac troponin I levels and RF ablation procedures.
This study demonstrates that serum levels of cTnI are more
sensitive than CK-MB levels in detecting myocardial injury
incurred during RF ablation procedures. In our cohort of
118 consecutive patients undergoing RF ablation for a
variety of cardiac arrhythmias, only 32 (27%) had elevation
of CK-MB despite a significant number of RF lesions.
These results are consistent with previous reports of RF
ablation quantitating myocardial necrosis produced during
these procedures by determining CK and CK-MB, which
have failed to detect a significant injury in most patients
(1–9). Creatine kinase inactivation by RF ablation has been
proposed as a cause of underestimation of the total myocar-
dial injury incurred (10).
Cardiac troponin I is a more sensitive and specific marker
of myocardial injury. However, it has rarely been used
Table 3. Procedural Factors Associated With Higher Cardiac Troponin I Levels After RF
Ablation
Procedural Factor Cardiac Troponin I Levels (ng/ml)
Number of RF lesions (r 5 0.53, p , 0.0001)
$10 lesions (n 5 58) 3.26 6 2.88
,10 lesions (n 5 60) 1.27 6 1.43
p Value 0.0001
Site of RF ablation*
Ventricular (n 5 15) . atrial (n 5 17) .
annular (n 5 86)
3.56 6 2.90 . 2.36 6 2.29
. 2.00 6 2.37
p Value 0.012
Approach to mitral annulus**
Transaortic (n 5 13) . transseptal (n 5 15) 4.04 6 3.85 . 1.46 6 2.54
p Value 0.004
Duration of RF ablation (r 5 0.50, p , 0.0001)
*Number of RF lesions: 15 6 10 (ventricular) versus 24 6 36 (atrial) versus 16 6 21 (annular) (p 5 NS); **number of RF lesions:
20 6 26 (transaortic) versus 13 6 11 (transseptal) (p 5 NS).
NS 5 nonsignificant; RF 5 radiofrequency.
Figure 2. Procedural factors affecting peak cTnI levels during RF
ablation include site of RF ablation and number of RF lesions
produced. Highest cTnI levels are measured during ablation of
ventricular myocardium (V-site), intermediate levels during abla-
tion of atrial myocardium (Atrial site) and lowest levels during
ablation at annular sites. With a TS approach to the mitral
annulus, where lesions are applied to the atrial aspect, cTnI levels
are lower compared with a TAo approach with lesions mainly
applied at the ventricular aspect. When more than 10 RF lesions
are produced, cTnI levels are significantly higher than with fewer
lesions. cTnI 5 cardiac troponin I; RF 5 radiofrequency; TAo 5
transaortic; TS 5 transseptal.
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previously to monitor myocardial injury during RF ablation.
Our results show that, overall, 68% of patients undergoing
RF ablation have abnormal cTnI levels, a significantly
higher percentage representing a 2.5-fold increase, com-
pared with those detected by CK-MB. This is consistent
with the results of two recent studies, one utilizing cardiac
troponin T measurements in a smaller patient group of 28
patients undergoing RF ablation, where 93% of patients had
abnormal cardiac troponin T levels compared with only 36%
having abnormal CK-MB levels (16) and the other study
using cTnI in 51 patients having RF ablation, where 92% of
patients had an abnormal cTnI level versus 63% of patients
having elevated CK-MB levels (17). Cardiac troponin I has
been considered more specific than cardiac troponin T,
since cTnI is never present in skeletal muscle and is not
affected by renal insufficiency (14). Another major advan-
tage of cTnI relates to its normal levels (in contrast to a
moderate increase in CK-MB) reported during electrical
cardioversion, indicating the absence of detectable myocar-
dial lesion even for high energy cardioversion (19). Deter-
mining cTnI rather than CK-MB in such a setting helps
detect true myocardial injury. This was the case with one
patient in our ablation group who required multiple cardio-
versions for recurring atrial fibrillation (Table 2). Further-
more, all but one patient in the control group had normal
cTnI levels, despite some who were cardioverted for ar-
rhythmia termination.
Procedural correlates. A correlation between cTnI levels
and the number of RF current applications has been recently
reported (17) and is also confirmed by our study. Patients
having more than 10 RF current applications had much
higher cTnI levels. However, the relatively weak overall
correlation (r 5 0.53) may be related to the fact that not all
RF applications resulted in effective lesion formation, either
due to unstable catheter position or our practice of inter-
rupting RF application within 5 to 15 s if it was unsuccessful
or if a minimum temperature of 48°C to 50°C could not be
achieved within this time frame. Due to a lack of consistent
logging of peak temperature during the procedures, a
correlation of greater cTnI levels with higher achieved
temperature cannot be established with accuracy.
Another important correlation detected in this study was
between the peak cTnI levels and the site of RF ablation. To
our knowledge, this study is the first one to show a
correlation between the degree of myocardial injury incurred
during RF ablation as reflected by cTnI levels and the
specific site of RF ablation, as well as the approach to the
mitral annulus. Lesions created in the ventricular myocar-
dium, albeit numerically fewer, apparently entailed more
extensive myocardial injury as reflected by the higher cTnI
levels when compared with those measured during RF
application in the atrial myocardium or in the annuli (Table
3, Fig. 2). Annular lesions produced the lowest increase in
cTnI levels. However, at least for the lesions applied to the
mitral annulus, this increase was dependent on the approach
to the annulus, with significantly higher levels observed
during the transaortic approach, where ventricular lesions
were produced most often, compared with the transseptal
technique where lesions were applied to the atrial aspect of
the annulus. It is important to note that this result could not
be ascribed to a significantly greater number of RF lesions
applied with the transseptal approach (p 5 NS, Table 3).
Also, of 32 patients having only one to three RF lesions
(mostly at annular sites, n 5 27) and relatively low peak
cTnI levels (1.08 6 1.13 ng/ml), 50% had abnormal cTnI
values, whereas only one of these patients (3.1%) had an
abnormal CK-MB level (p , 0.001). This demonstrates the
very high sensitivity of cTnI in detecting minor myocardial
injury.
Study limitations. This study dealt with a rather hetero-
geneous population in terms of different underlying arrhyth-
mia substrate and, therefore, different approaches to cathe-
ter ablation. However, this fact has allowed for a better
understanding of the variable degree of myocardial injury
incurred with RF ablation applied at different sites. Another
limitation of this study was the lack of consistent logging of
peak temperature during the procedures and, thus, an
association of higher cTnI levels with greater temperature
measurements could not be established.
Clinical implications. This study offers new insight into
the assessment of myocardial injury incurred during RF
ablation. Monitoring of myocardial tissue damage, even of a
minor degree, is more accurate with the use of cTnI, which
is a more sensitive and specific marker than CK-MB. Our
study also determined the procedural correlates that char-
acterize such myocardial injury, demonstrating its depen-
dence on the number of lesions applied and the site of RF
ablation. More extensive tissue damage is produced during
ablation of ventricular myocardium, rather than during
ablation performed at atrial or annular sites, the latter
producing the lowest increase in cTnI levels. Thus, the
results of this study raise important issues concerning
efficacy and safety and preferable target sites of RF ablation.
It suggests that to minimize the extent of myocardial injury,
the operator, apart from striving to be successful with as few
RF applications as possible, should also aim to deliver them
at the annular or atrial side, if possible. This may be
particularly important in younger patients (20), in light of
previous studies indicating possible developmental effects in
younger hearts (21). Finally, although it became apparent
that myocardial injury produced by RF ablation can be
detected more accurately with the cTnI rather than CK-MB
assay, its prognostic significance remains to be explored in
future studies.
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